CRT develops and commercialises exciting new discoveries in cancer research. We’re the meeting point between academia and industry. Our deep understanding of both perspectives enables us to translate promising research into commercial propositions to deliver patient benefit and commercial value that will support further cancer research.
Exclusive rights to £300m of cancer research per yearOur marketed drugs include Temodal, Zytiga and Erivedge. What’s next?